Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorMemorial Sloan Kettering Cancer Center

About this trial

The investigators are doing this research study to assess the percentage of patients receiving stem cell transplantation for the type of blood cancer you have. They want to know how many patients get a transplant and why some patients do get a transplant while others do not. Also they want to explore why some patients elect not to undergo stem cell transplantation, when it is recommended by their physicians.

Eligibility criteria

Qualifiers

Patients with newly diagnosed or relapsed acute leukemia. Patients undergoing reinduction due to primary induction failure are also eligible. Patients with acute leukemia will be enrolled to Arm A

Clinically significant cytopenia of at least 2 cell lines affected; Hgb<10,

Platelet<100,000, absolute neutrophil count<1000

Bone marrow blasts >5% and any level of circulating blasts

Disqualifiers

Patients with polycythemia vera (PV) and essential thrombocytosis (ET)

Trial design

Treatments tested in this trial

  • assessments

Treatment groups

1,365 Participants
are divided into 3 treatment groups